Literature DB >> 27277244

Ultrasonography of intrahepatic bile duct adenoma with renal cell carcinoma: correlation with pathology.

Manabu Watanabe1, Kazue Shiozawa2, Takashi Ikehara2, Miue Ichimori2, Mie Shinohara2, Yoshinori Kikuchi2, Koji Ishii2, Tetsuo Nemoto3, Kazutoshi Shibuya3, Yasukiyo Sumino2.   

Abstract

Intrahepatic bile duct adenoma (BDA) is a relatively rare benign tumor. Most cases are incidentally discovered during surgery or autopsy. We report here the co-existence of renal cell carcinoma and BDA mimicking metastasis in a 30-year-old female. An isoechoic nodule with a hypoechoic rim sized 10 × 9 mm was observed by ultrasonography in S2 of the liver. On contrast-enhanced ultrasonography (CEUS), the mass was enhanced in the early vascular phase and a defect with a clear border appeared in the post-vascular phase. We present the ultrasonography findings of BDA, including those yielded by CEUS using Sonazoid, along with the gross and microscopic pathological correlation.

Entities:  

Keywords:  Bile duct adenoma; Contrast-enhanced ultrasonography; Sonazoid

Year:  2013        PMID: 27277244     DOI: 10.1007/s10396-012-0428-x

Source DB:  PubMed          Journal:  J Med Ultrason (2001)        ISSN: 1346-4523            Impact factor:   1.314


  13 in total

Review 1.  Radiologic features of intrahepatic bile duct adenoma: a look at the surface of the liver.

Authors:  T Tajima; H Honda; T Kuroiwa; K Yoshimitsu; H Irie; H Aibe; K Taguchi; M Shimada; K Masuda
Journal:  J Comput Assist Tomogr       Date:  1999 Sep-Oct       Impact factor: 1.826

2.  Magnetic resonance findings of bile duct adenoma with calcification.

Authors:  Eriko Maeda; Kazuhito Uozumi; Nobuyuki Kato; Masaaki Akahane; Shinichi Inoh; Yousuke Inoue; Yoshifumi Beck; Akiteru Goto; Masatoshi Makuuchi; Kuni Ohtomo
Journal:  Radiat Med       Date:  2006-07

3.  Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) - update 2008.

Authors:  M Claudon; D Cosgrove; T Albrecht; L Bolondi; M Bosio; F Calliada; J-M Correas; K Darge; C Dietrich; M D'Onofrio; D H Evans; C Filice; L Greiner; K Jäger; N de Jong; E Leen; R Lencioni; D Lindsell; A Martegani; S Meairs; C Nolsøe; F Piscaglia; P Ricci; G Seidel; B Skjoldbye; L Solbiati; L Thorelius; F Tranquart; H P Weskott; T Whittingham
Journal:  Ultraschall Med       Date:  2008-02       Impact factor: 6.548

Review 4.  How many types of biliary hamartomas and adenomas are there?

Authors:  W M Tsui
Journal:  Adv Anat Pathol       Date:  1998-01       Impact factor: 3.875

5.  The so-called bile duct adenoma is a peribiliary gland hamartoma.

Authors:  P S Bhathal; N R Hughes; Z D Goodman
Journal:  Am J Surg Pathol       Date:  1996-07       Impact factor: 6.394

Review 6.  Bile duct adenoma. A study of 152 cases.

Authors:  G S Allaire; L Rabin; K G Ishak; I A Sesterhenn
Journal:  Am J Surg Pathol       Date:  1988-09       Impact factor: 6.394

Review 7.  Imaging findings of intrahepatic bile duct adenoma (peribiliary gland hamartoma): a case report and literature review.

Authors:  You Sung Kim; Sung Eun Rha; Soon Nam Oh; Seung Eun Jung; Yu Ri Shin; Byung Gil Choi; Jae Young Byun; Eun Sun Jung; Dong Goo Kim
Journal:  Korean J Radiol       Date:  2010-08-27       Impact factor: 3.500

8.  Sonazoid-enhanced ultrasonography for diagnosis of hepatic malignancies: comparison with contrast-enhanced CT.

Authors:  Kinuyo Hatanaka; Masatoshi Kudo; Yasunori Minami; Kiyoshi Maekawa
Journal:  Oncology       Date:  2008-12-17       Impact factor: 2.935

9.  A benign tumour of the liver mimicking malignant liver disease--cholangiocellular adenoma.

Authors:  Andre Ignee; Fabio Piscaglia; Michaela Ott; Veronica Salvatore; Christoph F Dietrich
Journal:  Scand J Gastroenterol       Date:  2009       Impact factor: 2.423

10.  Evaluation of the hemodynamic status of focal hepatic lesions 20 mm or less in diameter by contrast-enhanced ultrasonography using Sonazoid.

Authors:  Kazue Shiozawa; Manabu Watanabe; Yasukiyo Sumino
Journal:  Intervirology       Date:  2009-06-26       Impact factor: 1.763

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.